| Nanosonics Limited (NAN) ORDINARY FULLY PAID |
Health Care |
$1,122 |
Update - Notification of buy-back - NAN
|
10 Mar 2026 9:22AM |
$3.570 |
$3.700 |
risen by
3.64%
|
|
| Dexus (DXS) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$6,443 |
Update - Notification of buy-back - DXS
|
10 Mar 2026 9:21AM |
$6.220 |
$5.990 |
fallen by
3.70%
|
|
| Laramide Resources Ltd (LAM) CHESS DEPOSITARY INTERESTS 1:1 |
Energy |
$16 |
Notification regarding unquoted securities - LAM
|
10 Mar 2026 9:21AM |
$0.830 |
$0.760 |
fallen by
8.43%
|
|
| Ion Video Ltd (IOV) ORDINARY FULLY PAID |
Information Technology |
$20 |
Independent Validation of New Patent Filing
|
10 Mar 2026 9:21AM |
$0.210 |
$0.210 |
fallen by
0%
|
|
| Terra Critical Minerals Limited (T92) ORDINARY FULLY PAID |
Energy |
$13 |
Change in substantial holding
|
10 Mar 2026 9:21AM |
$0.140 |
$0.089 |
fallen by
36.43%
|
|
| Dimerix Limited (DXB) ORDINARY FULLY PAID |
Health Care |
$195 |
Dimerix Phase 3 Trial Last Patient Receives First Dose
|
10 Mar 2026 9:21AM |
$0.375 |
$0.325 |
fallen by
13.33%
|
|
DXB - Price-sensitive ASX Announcement
Full Release
Key Points
- 333 patients have been randomised and dosed in the ACTION3 Phase 3 clinical study.
- The final enrolment reached 333 adult patients in the ACTION3 Phase 3 trial.
- Paediatric patient recruitment remains ongoing as an independent cohort.
- The full 2-year study is expected to complete in March 2028.
- The trial has successfully passed seven scheduled Independent Data Monitoring Committee reviews.
- The ACTION3 Phase 3 study is a pivotal multi-centre, randomised, double-blind, placebo-controlled study.
- The study is aimed at generating evidence of proteinuria reduction and kidney function (eGFR slope).
- Dimerix plans further steps including a statistical analysis of the ACTION3 study in line with FDA guidance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tetratherix Limited (TTX) ORDINARY FULLY PAID |
Health Care |
$117 |
Tutelix Update
|
10 Mar 2026 9:21AM |
$3.810 |
$4.310 |
risen by
13.12%
|
|
TTX - Price-sensitive ASX Announcement
Full Release
Key Points
- Tutelix is a clinician-friendly spacer for prostate cancer radiation therapy.
- Enables higher radiation doses in shorter timeframes.
- Series A funding round completed, raising approximately $5 million.
- Clinical trials progressing in Australia and the US.
- US-FDA 510(k) clearance expected by 2028.
- No adverse events reported in trials, demonstrating safety and efficacy.
- Product offers commercial potential with superior performance and cost benefits.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Metal Bank Limited (MBK) ORDINARY FULLY PAID |
Materials |
$17 |
Outstanding Gold Recovery Results for Seven Leaders
|
10 Mar 2026 9:19AM |
$0.023 |
$0.020 |
fallen by
13.04%
|
|
MBK - Price-sensitive ASX Announcement
Full Release
Key Points
- Single pass Falcon gravity gold recovery of 72.5%
- Intensive leaching recovered >99% of gold
- Bottle roll leaching recovered 92.6% from Falcon tails
- High nugget effect indicating potential grade upside
- JORC 2012 Mineral Resource Estimate: 138,000t @ 1.4g/t Au
- Whiteheads Gold Project covers ~380km², 80km NE of Kalgoorlie
- MBK committed to expediting WA gold production strategy
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| COSOL Limited (COS) ORDINARY FULLY PAID |
Information Technology |
$36 |
Notification of cessation of securities - COS
|
10 Mar 2026 9:17AM |
$0.230 |
$0.200 |
fallen by
13.04%
|
|
| Polymetals Resources Ltd (POL) ORDINARY FULLY PAID |
Materials |
$214 |
Notification of cessation of securities - POL
|
10 Mar 2026 9:17AM |
$0.900 |
$0.695 |
fallen by
22.78%
|
|
| North Stawell Minerals Ltd (NSM) ORDINARY FULLY PAID |
Materials |
$10 |
Air Core Commences at Caledonia and Darlington Projects
|
10 Mar 2026 9:14AM |
$0.030 |
$0.027 |
fallen by
10%
|
|
NSM - Price-sensitive ASX Announcement
Full Release
Key Points
- Air core drilling program of 2,000-2,500 meters commenced.
- Projects located at Caledonia and Darlington, Victoria.
- NSD057 drill hole at Darlington revealed 2.3m at 29.3 g/t Au.
- Darlington mineralisation parallels historic trends, open in all directions.
- Caledonia and Darlington are priority targets along a 3.6 km trend.
- Victorian-based AMWD conducting the drilling.
- Results anticipated by early to mid-April 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| DPM Metals Inc. (DPM) CDI 1:1 FOREIGN EXEMPT TSX |
Materials |
$865 |
DPM Announces Filing of Technical Report for Chelopech Mine
|
10 Mar 2026 9:14AM |
$54.970 |
$47.500 |
fallen by
13.59%
|
|
DPM - Price-sensitive ASX Announcement
Full Release
Key Points
- DPM Metals Inc. announced the filing of a technical report for the Chelopech mine.
- The report aligns with NI 43-101 standards for mineral projects.
- It supports updates to the Mineral Resource and Reserve estimates and life of mine plan.
- DPM aims to become a mid-tier precious metals company.
- The report and related news releases are available on SEDAR+ and the company's website.
- The company operates in Bulgaria, Bosnia and Herzegovina, Serbia, and Ecuador.
- DPM trades on the Toronto and Australian Stock Exchanges.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Black Rock Mining Limited (BKT) ORDINARY FULLY PAID |
Materials |
$31 |
Half Year Report and Accounts
|
10 Mar 2026 9:13AM |
$0.017 |
$0.015 |
fallen by
14.71%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$52 |
Trading Halt
|
10 Mar 2026 9:12AM |
$0.230 |
$0.145 |
fallen by
36.96%
|
|
IMU - Price-sensitive ASX Announcement
Full Release
Key Points
- Imugene Limited's securities are in a trading halt.
- The trading halt is due to a pending announcement on a proposed capital raising.
- The halt will last until the announcement is made or until normal trading resumes on 12 March 2026.
- Imugene requested the halt under ASX Listing Rule 17.1.
- No other information is required to inform the market about the halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| St George Mining Limited (SGQ) ORDINARY FULLY PAID |
Materials |
$443 |
Key Appointment of Principal Geologist at Araxa
|
10 Mar 2026 9:11AM |
$0.125 |
$0.115 |
fallen by
8%
|
|
SGQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Appointment of Ms. Carla Grasso as Principal Geologist.
- Focus on accelerating the Araxá Rare Earths-Niobium Project.
- Ms. Grasso has 21 years of experience, including at a nearby phosphate mine.
- Recent resource upgrade at Araxá Project boosting TREO and niobium resources.
- Araxá Project is positioned near world-leading niobium operations.
- Local government support and infrastructure aid project development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Whitefield Income Limited (WHI) ORDINARY FULLY PAID |
Financials |
$294 |
Net Tangible Asset Backing - Feb 26
|
10 Mar 2026 9:11AM |
$1.350 |
$1.335 |
fallen by
1.11%
|
|
| Guzman Y Gomez Limited (GYG) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,692 |
Update - Notification of buy-back - GYG
|
10 Mar 2026 9:10AM |
$18.940 |
$16.520 |
fallen by
12.78%
|
|
| HitIQ Limited (HIQ) ORDINARY FULLY PAID |
Health Care |
$9 |
Continued Suspension of Class from Quotation - HIQOA Only
|
10 Mar 2026 9:10AM |
$0.018 |
$0.015 |
fallen by
16.67%
|
|
| Orica Limited (ORI) ORDINARY FULLY PAID |
Materials |
$9,434 |
First Half Business Update
|
10 Mar 2026 9:09AM |
$21.660 |
$20.300 |
fallen by
6.28%
|
|
ORI - Price-sensitive ASX Announcement
Full Release
Key Points
- Orica is not currently experiencing immediate constraints due to the Middle East conflict.
- Orica products are generally not transported through the Straits of Hormuz.
- The company is monitoring the situation and leveraging its global network to mitigate potential impacts on energy or raw material costs.
- Orica's CEO, Sanjeev Gandhi, expresses satisfaction with the strong start to the 2026 financial year.
- The company is focused on operational excellence and maintaining continuity of supply despite volatile market conditions.
- Orica remains committed to disciplined capital management and advancing growth initiatives.
- The half-year results will be announced on 7 May 2026.
- Orica aims for net zero emissions by 2050, aligning with the Paris Agreement goals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EQT Holdings Limited (EQT) ORDINARY FULLY PAID |
Financials |
$539 |
Appendix 3Ys - NED Share Plan
|
10 Mar 2026 9:09AM |
$20.080 |
$20.110 |
risen by
0.15%
|
|
| Orthocell Limited (OCC) ORDINARY FULLY PAID |
Health Care |
$203 |
Orthocell Appoints UK Distributor for Remplir
|
10 Mar 2026 9:08AM |
$0.800 |
$0.750 |
fallen by
6.25%
|
|
OCC - Price-sensitive ASX Announcement
Full Release
Key Points
- Orthocell has appointed LEDA Orthopaedics as the exclusive distributor for Remplirâ„¢ in the UK.
- Orthocell submitted a regulatory application to the British Standards Institution for approval to distribute Remplir in the UK/EU market.
- The UK/EU peripheral nerve repair market is valued at approximately $750 million.
- Regulatory approval for Remplir in the UK is anticipated in the third quarter of fiscal year 2026.
- LEDA Orthopaedics has extensive experience in orthopaedic technologies and maintains strong relationships with UK surgeons.
- Early distributor appointments are made to prepare for rapid commercial launch post-approval.
- Orthocell's Australian-based commercial teams will support the UK rollout, leveraging proven medical education programs.
- Remplir is already approved and selling in several countries, including Australia, New Zealand, Singapore, the US, and Hong Kong.
- Orthocell reported approximately $49 million in cash reserves as of 31 December 2025 to support its global distribution strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| GPT Group (GPT) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$8,678 |
Notice of Annual General Meeting/Proxy Form
|
10 Mar 2026 9:06AM |
$4.670 |
$4.530 |
fallen by
3%
|
|
| Sports Entertainment Group Limited (SEG) ORDINARY FULLY PAID |
Communication Services |
$73 |
Notification of buy-back - SEG
|
10 Mar 2026 9:06AM |
$0.240 |
$0.260 |
risen by
8.33%
|
|
| Life360 Inc (360) CDI 3:1 FOREIGN EXEMPT XNGS |
Information Technology |
$3,528 |
SEC Form 4
|
10 Mar 2026 9:06AM |
$20.400 |
$19.290 |
fallen by
5.44%
|
|
| Matsa Resources Limited (MAT) ORDINARY FULLY PAID |
Materials |
$83 |
Campaign 2 Final Results Devon Pit Gold Mine
|
10 Mar 2026 9:05AM |
$0.094 |
$0.085 |
fallen by
9.57%
|
|
MAT - Price-sensitive ASX Announcement
Full Release
Key Points
- $28.74M in gold sales from Campaign 2
- 4,074 oz Au produced and sold
- Average sale price of $7,054 per oz
- 51,562 dry tonnes processed
- Head grade increased to 2.86g/t
- Recovery improved to 86.16%
- Mining for Campaign 3 to commence May 28, 2026
- Current cash balance of $18.59M
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.